The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Market Size Expansion Is Predicted For The Tumor Blood Testing Market Between 2026 And 2030?
The tumor blood testing market has seen rapid growth in recent years. It is projected to expand from $5.98 billion in 2025 to $6.78 billion in 2026, achieving a compound annual growth rate (CAGR) of 13.3%. Historically, this growth can be attributed to factors such as an increase in cancer prevalence, the limitations associated with tissue biopsies, progress in genomic testing, greater funding for oncology research, and a rising demand for non-invasive diagnostic solutions.
The tumor blood testing market size is projected to see significant expansion in the coming years. It is expected to grow to $11.13 billion in 2030, demonstrating a compound annual growth rate (CAGR) of 13.2%. This growth during the forecast period can be attributed to factors such as early cancer screening programs, AI-enabled genomic analysis, the evolution of personalized medicine, the broader application of companion diagnostics, and increased adoption in clinical trials. Major trends anticipated in this period include the widespread adoption of liquid biopsy, the development of multi-cancer early detection methods, enhanced minimal residual disease monitoring, advancements in personalized oncology testing, and the identification of high-sensitivity biomarkers.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=28343&type=smp
Which Growth Drivers Are Contributing To The Progress Of The Tumor Blood Testing Market?
The escalating occurrence of cancer is projected to propel the expansion of the tumor blood testing market over the next few years. Demographic shifts towards older populations, coupled with exposure to various risk factors like unhealthy eating habits, tobacco use, and environmental contamination, are contributing to a greater number of cancer cases, thereby boosting the need for timely diagnostic techniques. This method, known as tumor blood testing, offers a less intrusive way to identify cancer markers in the bloodstream, allowing for detection prior to the onset of overt symptoms. Such capabilities facilitate prompt diagnoses, earlier therapeutic interventions, better results for patients, and continuous surveillance of disease advancement and treatment efficacy. For instance, in May 2024, the National Cancer Institute, a US-based government agency, reported that as of January 2022, the United States had an estimated 18.1 million cancer survivors, with projections expected to reach 26 million by 2040. Consequently, the rising occurrence of cancer is significantly propelling the expansion of the tumor blood testing market.
Which Market Segments Are Examined In The Tumor Blood Testing Market Study?
The tumor blood testing market covered in this report is segmented –
1) By Test Type: Circulating Tumor Cells (CTC) Tests, Circulating Tumor DNA (CtDNA) Tests, Exosome-Based Tests, Other Test Types
2) By Technology: Polymerase Chain Reaction (PCR)-Based Testing, Next-Generation Sequencing, Immunoassays
3) By Cancer Type: Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer, Melanoma
4) By Application: Early Cancer Screening, Therapy Selection, Treatment Monitoring, Recurrence Monitoring
5) By End User: Hospitals, Diagnostic Laboratories, Research Institutes, Other End-Users
Subsegments:
1) By Circulating Tumor Cells Tests: Isolation Of Tumor Cells, Enumeration Of Tumor Cells, Characterization Of Tumor Cells
2) By Circulating Tumor DNA Tests: Mutation Detection Of Tumor DNA, Methylation Analysis Of Tumor DNA, Copy Number Variation Analysis Of Tumor DNA, Fragmentation Analysis Of Tumor DNA
3) By Exosome-Based Tests: Protein Profiling Of Exosomes, RNA Profiling Of Exosomes, Lipid Profiling Of Exosomes, Surface Marker Analysis Of Exosomes
4) By Other Tests: Circulating RNA Tests, Tumor Educated Platelet Tests, Protein Biomarker Panels, Multiomics Blood Tests, Immuno Oncology Biomarker Tests
Which Trends Are Influencing The Tumor Blood Testing Market?
Key companies in the tumor blood testing industry are channeling their efforts into developing cutting-edge technologies, such as non-invasive liquid biopsy methods, to enable earlier detection of cancer, monitor the efficacy of treatments, and more efficiently assess the progression of diseases. Non-invasive liquid biopsy technologies are diagnostic examinations that detect and analyze cancer-related biomarkers from bodily fluids, presenting a safer and more convenient option compared to traditional tissue biopsies. For example, in February 2024, Delfi Diagnostics, a US-based biotechnology company, in collaboration with Immunocore Holdings plc, a UK-based biotechnology company, launched the DELFI-Tumor Fraction (DELFI-TF) assay, a blood test for cancer monitoring. It scrutinizes cell-free DNA (cfDNA) fragments within the bloodstream to gauge tumor burden and how well treatment is working. This fragmentome-based liquid biopsy provides a non-invasive, cost-effective alternative to existing methods, requiring only a minimal plasma sample and yielding results within two weeks.
Who Are The Primary Competitors In The Tumor Blood Testing Market?
Major companies operating in the tumor blood testing market are Bio-Techne Corporation, Roche Holding AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Siemens Healthineers AG, Illumina Inc., Sysmex Corporation, Bio-Rad Laboratories Inc., Natera Inc., Myriad Genetics Inc., Neogenomics Laboratories Inc., Guardant Health Inc., Foundation Medicine Inc., Adaptive Biotechnologies Corporation, Freenome Holdings Inc., Grail Inc., Personal Genome Diagnostics Inc., Exosome Diagnostics Inc., Agena Bioscience Inc., Menarini Silicon Biosystems S.p.A.
Read the full tumor blood testing market report here:
https://www.thebusinessresearchcompany.com/report/tumor-blood-testing-global-market-report
What Are The Leading Geographic Regions In The Tumor Blood Testing Market?
North America was the largest region in the tumor blood testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the tumor blood testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Tumor Blood Testing Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=28343&type=smp
Browse Through More Reports Similar to the Global Tumor Blood Testing Market 2026, By The Business Research Company
Hemato Oncology Testing Market Report 2026
https://www.thebusinessresearchcompany.com/report/hemato-oncology-testing-global-market-report
Cancer Diagnostics Market Report 2026
https://www.thebusinessresearchcompany.com/report/cancer-diagnostics-global-market-report
Blood Screening Market Report 2026
https://www.thebusinessresearchcompany.com/report/blood-screening-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model